On September 8, 2021, Hangzhou Biotest Biotech Co., Ltd. was listed on SSE STAR Market. Stock code: 688767. The issue price is 34.55 yuan/share, and the opening price is 80.50 yuan/share. Due to the COVID-19 in 2020, the c Biotest Biotech's sales was 865 million yuan, a year-on-year increase of 656%; net profit was 435 million yuan, a year-on-year increase of 1457.05%; the gross profit margin of main products was 75.14%, a year-on-year increase of 76.23%.

Founded in 2008, Biotest Biotech is a national high-tech enterprise specializing in the research and development, production and sales of POCT diagnostic reagents. It is one of the leading companies in the POCT industry in my country. Biotest Biotech is committed to providing innovative, immediate, high-quality diagnostic products and solutions for global users to meet the endless medical needs. Biotest Biotech flagship facility consists of an area of 25,000 square meters with registered capital of 80 million RMB.

Biotest Biotech 's current products cover five major testing areas, i fertility health, drug testing/toxicology, infectious disease identification, tumor marker detection and cardiac maker monitoring, which are widely used in medical institutions at all levels at home and abroad, like employee screening, medical diagnostics, judicial compliance and military testing, etc. Many products have obtained China NMPA registration, EU CE certification and US FDA510(k) certification.